Business Context and Reporting Period
Company: Access Pharmaceuticals, Inc. (Note: Metadata listed "Abeona Therapeutics," but the filing text identifies the registrant as Access Pharmaceuticals, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the period ended September 30, 2006.
Business Overview: An emerging pharmaceutical company focused on oncology and vitamin-targeted drug delivery technologies. The company sold its oral care and dermatology business unit to Uluru, Inc. in October 2005 to focus on R&D. The company has been unprofitable since inception with an accumulated deficit of $76.4 million as of September 30, 2006.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2006 | Nine Months Ended Sept 30, 2006 | Sept 30, 2006 Balance Sheet |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,015,000) | $(10,202,000) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.57) | $(2.89) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $482,000 |
| Short-Term Investments | N/A | N/A | $223,000 |
| Total Current Assets | N/A | N/A | $5,468,000 |
| Total Current Liabilities | N/A | N/A | $15,772,000 |
| Working Capital | N/A | N/A | $(10,304,000) |
| Total Debt (Current + Long-Term) | N/A | N/A | $17,608,000 |
| Accumulated Deficit | N/A | N/A | $(76,367,000) |
Cash Flow (Nine Months Ended Sept 30, 2006):
- Net cash used in operating activities: $(4,192,000)
- Net cash used in investing activities: $(101,000)
- Net cash provided by financing activities: $4,426,000 (primarily from proceeds of secured convertible notes).
Material Changes vs. Prior Period
- Net Loss: For the nine months ended Sept 30, 2006, net loss increased by $1.9 million to $10.2 million compared to $8.3 million in the same period in 2005. This increase is largely driven by a $1.1 million unrealized loss on the fair value of warrants and conversion features associated with convertible notes.
- Interest Expense: Interest and other expense surged to $5.2 million for the nine months of 2006 from $1.2 million in 2005, primarily due to the amortization of discounts on secured convertible notes.
- Operating Expenses: General and administrative expenses decreased by $1.1 million year-over-year (nine months) due to the elimination of costs associated with the former CEO separation agreement and lower professional fees, partially offset by higher stock-based compensation and patent costs.
- Discontinued Operations: The company reported no discontinued operations in 2006, whereas 2005 included a loss of $2.1 million related to the sale of the oral/topical business and closure of the Australian lab.
Guidance, Outlook, Risks, and Contingencies
Liquidity and Going Concern: Management states that existing capital resources, including receivables from Uluru, Inc., are sufficient to fund operations for approximately seven months (through May 2007), excluding debt obligations. The company explicitly states it does not have sufficient funds to repay convertible notes due in March and April 2007. Auditors have expressed significant doubt about the company's ability to continue as a going concern.
Debt Obligations:
- Approximately $5.0 million of Senior Convertible Notes due March 31, 2007.
- Approximately $4.0 million of Convertible Subordinated Notes due April 2007.
- Approximately $5.5 million of Convertible Subordinated Notes due September 2010.
- Accrued interest payable of $1.5 million as of Sept 30, 2006.
Recent Financing: On October 24, 2006 (post-period), the company sold $500,000 of 7.5% convertible notes and warrants, receiving $450,000 in net proceeds. In February 2006, the company raised $4.5 million net via similar instruments.
Risk Factors:
- Uluru Receivable: A $3.7 million anniversary payment due from Uluru, Inc. on October 12, 2006, was not paid. Uluru assured payment is forthcoming upon closing of their financing, but terms are being negotiated.
- SEDA Access: The Standby Equity Distribution Agreement (SEDA) with Cornell Capital Partners ($15M capacity) cannot be accessed until a post-effective amendment to the registration statement is filed and declared effective by the SEC.
- Internal Controls: The company identified material weaknesses in internal controls regarding staffing and segregation of duties, though hiring is underway to correct this.
- Regulatory: Success depends on FDA approvals for drug candidates (e.g., ProLindac, MuGard), which are subject to significant uncertainty and delay.
Investor Verification Checklist
- Debt Maturity: Verify the company's ability to refinance or repay ~$9 million in debt due in March and April 2007.
- Uluru Payment: Confirm the status of the $3.7 million receivable from Uluru, Inc. and the likelihood of collection.
- SEDA Status: Check if the post-effective amendment for the Standby Equity Distribution Agreement has been filed and declared effective by the SEC.
- Cash Burn Rate: Monitor the monthly cash burn rate (projected at ~$625,000) against current cash balances ($705,000 total liquid assets).
- Going Concern Opinion: Review the latest audit report for any updates on the "substantial doubt" regarding the company's ability to continue operations.